Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

K. Tabata; M. Watanabe; K. Naruishi; K. Edamura; T. Satoh; G. Yang; E. Abdel Fattah; J. Wang; A. Goltsov; D. Floryk; S. D. Soni; D. Kadmon; T. C. Thompson

doi:10.1038/pcan.2008.57

Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

K. Tabata, M. Watanabe, K. Naruishi, K. Edamura, T. Satoh, G. Yang, E. Abdel Fattah, J. Wang, A. Goltsov, D. Floryk, S. D. Soni, D. Kadmon, T. C. Thompson

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.

Original language	English
Pages (from-to)	301-309
Number of pages	9
Journal	Prostate Cancer and Prostatic Diseases
Volume	12
Issue number	3
DOIs	https://doi.org/10.1038/pcan.2008.57
Publication status	Published - 2009
Externally published	Yes

ASJC Scopus subject areas

Oncology
Urology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/pcan.2008.57

Cite this

Tabata, K., Watanabe, M., Naruishi, K., Edamura, K., Satoh, T., Yang, G., Abdel Fattah, E., Wang, J., Goltsov, A., Floryk, D., Soni, S. D., Kadmon, D., & Thompson, T. C. (2009). Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer and Prostatic Diseases, 12(3), 301-309. https://doi.org/10.1038/pcan.2008.57

Tabata, K, Watanabe, M, Naruishi, K, Edamura, K, Satoh, T, Yang, G, Abdel Fattah, E, Wang, J, Goltsov, A, Floryk, D, Soni, SD, Kadmon, D & Thompson, TC 2009, 'Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer', Prostate Cancer and Prostatic Diseases, vol. 12, no. 3, pp. 301-309. https://doi.org/10.1038/pcan.2008.57

@article{f9171b6e3a2f4671afd5b02580ea80c0,

title = "Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer",

abstract = "We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.",

author = "K. Tabata and M. Watanabe and K. Naruishi and K. Edamura and T. Satoh and G. Yang and {Abdel Fattah}, E. and J. Wang and A. Goltsov and D. Floryk and Soni, {S. D.} and D. Kadmon and Thompson, {T. C.}",

year = "2009",

doi = "10.1038/pcan.2008.57",

language = "English",

volume = "12",

pages = "301--309",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

AU - Tabata, K.

AU - Watanabe, M.

AU - Naruishi, K.

AU - Edamura, K.

AU - Satoh, T.

AU - Yang, G.

AU - Abdel Fattah, E.

AU - Wang, J.

AU - Goltsov, A.

AU - Floryk, D.

AU - Soni, S. D.

AU - Kadmon, D.

AU - Thompson, T. C.

PY - 2009

Y1 - 2009

N2 - We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.

AB - We evaluated the potential use of intraoperative gelatin matrix hemostatic sealant (GMHS; FloSeal; Baxter Healthcare) embedded with macrophages (Mφ) transduced with murine interleukin (IL)-12 recombinant adenoviral vector (G/Mφ/AdmIL-12) for prevention of recurrence of prostate cancer following radical prostatectomy. Application of G/Mφ/AdmIL-12 resulted in significant suppression of tumor growth and spontaneous lung metastases, a statistically significant survival advantage of the G/Mφ/AdmIL-12-treated animals, more efficient trafficking of Mφ to lymph nodes draining from the prostate and generation of systemic natural killer cell activity and tumor-specific cytolytic T lymphocyte responses compared to the controls in a preclinical mouse model of residual prostate cancer. Our data recommend this treatment as a novel adjuvant for prevention of local recurrence of prostate cancer following radical prostatectomy.

UR - http://www.scopus.com/inward/record.url?scp=70249088391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249088391&partnerID=8YFLogxK

U2 - 10.1038/pcan.2008.57

DO - 10.1038/pcan.2008.57

M3 - Article

C2 - 19104507

AN - SCOPUS:70249088391

SN - 1365-7852

VL - 12

SP - 301

EP - 309

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 3

ER -

Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this